AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies
NCT ID: NCT04835675
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
496 participants
OBSERVATIONAL
2021-03-12
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
NCT05343832
Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas
NCT05783973
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
NCT07176962
HCC Screening Using DNA Methylation Changes in ctDNA
NCT03483922
Pan-canceR Early DetectIon projeCT (PREDICT)
NCT04817306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer Arm
Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Benign Diseases Arm
Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-cancer early detection test
Blood collection and multi-cancer early detection testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to comply with study procedures
* Ability to provide a written informed consent
* Confirmed diagnosis or highly suspicious cases of hepatobiliary malignancies
* No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw
* Confirmed diagnosis of benign diseases of the hepatobiliary system
* No prior radical treatment of the benign diseases prior to study blood draw
Exclusion Criteria
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant
* Recipients of blood transfusion within 7 days prior to study blood draw
* Recipients of anti-microbial therapy within 14 days prior to study blood draw
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer
* Current diagnosis of other malignancies or multiple primary tumors
* Diagnosis of benign diseases by histopathological assessments
* Inability to characterize whether the lesion is malignant or benign
* Prior or ongoing treatment of cancer
* Current or history of malignancies or precancerous lesions
* No confirmed diagnosis or inability to characterize a benign disease
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou BR
UNKNOWN
Zhujiang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingxin Pan
Role: PRINCIPAL_INVESTIGATOR
Zhujiang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhujiang Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZJYY-2020006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.